A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford.
Pumpalova Y, Kozak M, von Eyben R, Fisher G, Kunz P, Chang D, Haraldsdottir S. A 20-year comparison of definitive chemoradiation with 5-FU versus capecitabine in anal cancer patients treated at Stanford. Journal Of Clinical Oncology 2018, 36: 710-710. DOI: 10.1200/jco.2018.36.4_suppl.710.Peer-Reviewed Original ResearchAnal cancer patientsDisease-specific survivalCancer patientsFM groupCM groupDefinitive chemoradiationColostomy rateExact testCommon grade 2Higher colostomy rateIncidence of recurrenceLoco-regional recurrenceLog-rank testCause of deathFisher's exact testMann-Whitney U testAnal painInduction chemotherapyAnal cancerDefinitive radiotherapyDistant recurrenceOverall survivalMedian ageMost recurrencesRectal cancer